Drug Profile

SZN 8141

Alternative Names: SZN-8141

Latest Information Update: 10 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Surrozen
Class Bispecific antibodies; Eye disorder therapies; Trispecific antibodies
Mechanism of Action FZD4 protein stimulants; Vascular endothelial growth factors inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Age-related macular degeneration; Diabetic macular oedema

Most Recent Events

08 Sep 2026 Surrozen files an IND application with the US FDA for Diabetic macular oedema
07 Aug 2026 Surrozen plans to file an IND application with the US FDA in Diabetic macular oedema by the end of the third quarter of 2026
07 Aug 2026 Surrozen plans the phase Ib/IIa DUET trial for Diabetic macular oedema (Treatment-naïve) (Intravitreal) by year-end 2026

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com